Evidence map›Paper›PMID 42383996›Full record

SynthesisBritish journal of haematology2026

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

Daniele Caracciolo, Maria Rita Lombardo, Gianluca Reitano, Cristina Napoli, Lucia Fiorillo, Chiara Callerame, Mario Garritano, Alessio Bulotta, Maha Munir, Giulia Pensabene and 5 more

Abstract readNetwork Meta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Daniele CaraccioloDepartment of Experimental and Clinical Medicine (DMSC), Magna Graecia University, Catanzaro, Italy.
Maria Rita LombardoDepartment of Experimental and Clinical Medicine (DMSC), Magna Graecia University, Catanzaro, Italy.
Gianluca ReitanoDepartment of Experimental and Clinical Medicine (DMSC), Magna Graecia University, Catanzaro, Italy.
Cristina NapoliMedical and Translational Medical Oncology Units, and Phase 1 Trial Center in Oncology and Onco-Hematology, AOU Renato Dulbecco, Catanzaro, Italy.
Lucia FiorilloMedical and Translational Medical Oncology Units, and Phase 1 Trial Center in Oncology and Onco-Hematology, AOU Renato Dulbecco, Catanzaro, Italy.
Chiara CallerameMedical and Translational Medical Oncology Units, and Phase 1 Trial Center in Oncology and Onco-Hematology, AOU Renato Dulbecco, Catanzaro, Italy.
Mario GarritanoDepartment of Experimental and Clinical Medicine (DMSC), Magna Graecia University, Catanzaro, Italy.
Alessio BulottaDepartment of Experimental and Clinical Medicine (DMSC), Magna Graecia University, Catanzaro, Italy.
Maha MunirDepartment of Experimental and Clinical Medicine (DMSC), Magna Graecia University, Catanzaro, Italy.
Giulia PensabeneMedical and Translational Medical Oncology Units, and Phase 1 Trial Center in Oncology and Onco-Hematology, AOU Renato Dulbecco, Catanzaro, Italy.
Emiliano BarbieriHematology Division, Azienda Unità Sanitaria Locale Istituto di Ricerca e Cura a Carattere Scientifico of Reggio Emilia, Reggio Emilia, Italy.
Alberto BavieriDoctorate School of Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy.
Pierfrancesco TassoneDepartment of Experimental and Clinical Medicine (DMSC), Magna Graecia University, Catanzaro, Italy.
Pierosandro TagliaferriDepartment of Experimental and Clinical Medicine (DMSC), Magna Graecia University, Catanzaro, Italy.
Stefano LuminariHematology Division, Azienda Unità Sanitaria Locale Istituto di Ricerca e Cura a Carattere Scientifico of Reggio Emilia, Reggio Emilia, Italy.

Funding

Italian Ministry of Health PSC Salute 2014-2020-POS4 "Cal-Hub-Ria" T4-AN-09
6 · The paper itself

Abstract

Relapsed/refractory follicular lymphoma (R/R FL) remains a clinically challenging condition, with progressively declining benefit across consecutive lines of therapy. While anti-Cluster of Differentiation 20 (CD20) antibodies remain the therapeutic backbone, the optimal targeted or immune-based partner remains undefined. A systematic review and network meta-analysis (NMA) of 5 phase III and 1 phase II trials (2500 patients) evaluated seven anti-CD20-based combination strategies. Primary end-points were overall survival (OS) and progression-free survival (PFS); secondary end-points included objective response rate (ORR) and grade ≥3 adverse events. Treatments were ranked using surface under the cumulative ranking (SUCRA) values. Immune-activating strategies ranked highest across efficacy end-points. Epcoritamab plus rituximab (R

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, FollicularHumansRecurrenceRituximabTreatment OutcomeRituximabanti‐CD20 antibodiesbispecific antibodieschemotherapy‐freefollicular lymphomanetwork meta‐analysisrelapsed/refractory

Identifiers

PMID42383996
PMCPMC13570175

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.